Kate O’Neill

Community Spotlight Research Spotlight

Hope and Action for Down syndrome Alzheimer’s research on WDSD 2023

Each year, the Down syndrome community and our supporters – family, friends, businesses, organizations and…

Kate O’NeillMarch 21, 2023

Community Spotlight

An athlete’s heart and a charmer’s smile: meet Armond Maillard

March 21st is “Down Syndrome Awareness Day,” a day designated by the United Nations to…

Kate O’NeillMarch 17, 2023

Community Spotlight

Beyond Down Syndrome: The Friedman family turns experience into guidance

Parent, advocate, and published author, Steve Friedman has used his family's recent experiences to help…

Kate O’NeillMarch 15, 2023

Research News Research Spotlight

Fierce Biotech article highlights dearth of inclusion in Alzheimer’s research

"Alzheimer's meds are here. But for the Down syndrome community, it's still the 1980s" by…

Kate O’NeillMarch 2, 2023

Tau Tangles in Down syndrome related Alzheimer's disease

Press Release Research News Research Spotlight

With support from Lilly, LuMind IDSC launches key research and awareness activities to advance Down syndrome research

2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research…

Kate O’NeillFebruary 23, 2023

Down syndrome brain and Alzheimer's disease

Community Spotlight Research Spotlight

Statement on accelerated approval of Leqembi to treat mild-stage Alzheimer’s disease in the general population

On Friday, January 6, the U.S. Food & Drug Administration (FDA) granted accelerated approval for…

Kate O’NeillJanuary 10, 2023

Research News Research Spotlight

New steps forward in treating Alzheimer’s disease with lecanemab: Clinical trial reveals clear efficacy in removing brain plaque

At an Alzheimer’s disease research conference last week, new clinical trial data was presented for…

Kate O’NeillDecember 5, 2022

Press Release Research Spotlight

DS-CTN Data and Safety Monitoring Board (DSMB)

LuMind IDSC and the Down Syndrome Clinical Trials Network are pleased to announce the launch…

Kate O’NeillNovember 16, 2022

Research Spotlight

Lecanemab: New Treatment for Alzheimer’s Disease

Eisai, a Japanese pharmaceutical company, and its partner Biogen, a Massachusetts-based biotechnology company, recently announced…

Kate O’NeillNovember 1, 2022

Long-COVID and its impact on cognitive function in adults with intellectual disability

Research Spotlight

NTG Publishes Advisory on Long-COVID in Adults with Intellectual Disability

In a recent report, the National Task Group on Intellectual Disabilities and Dementia Practices (NTG)…

Kate O’NeillOctober 17, 2022